CASI Pharmaceuticals (CASI) 10-K2018 FY Annual report

Filed: 29 Mar 19, 10:22am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abandon, abolished, accessible, accomplish, Acrotech, addMelphalan, administered, administering, Admission, advanceVincristine, analyzing, ancillary, andtenofovir, andVincristine, AOCI, appoint, AQSIQ, asMelphalan, assembled, attend, background, big, binding, Biopharma, budget, built, buy, CAC, candidatesMelphalan, carryforward, central, centralized, chain, Chaoyang, chapter, Chi, choice, choose, CohnReznick, commercializingMelphalan, commonly, comparison, complement, compromise, conclusion, concurrently, Conference, confidence, construct, constructed, construction, content, convincing, counterfeit, counterpart, county, court, CRGK, CSRC, database, defend, demand, Department, deprived, desirable, detachable, deviating, disagreement, discretion, disoproxil, disposition, dissolution, distributor, District, Document, documentation, Door, downgrade, dramatic, dropping, easier, economy, efficient, endorsement, engineering, entecavir, exploratory, extraordinary, extremely, facilitate, facilityin, flow, foregoing, forMelphalan, forward, founder, fourth, frequency, fumarate, genuine, George, goal, grown, Guokang, halt, hematology, highest, hope, Huazhen, Huicun, Huishan, illegally, immaterial, inaccurate, inadequate, includingMelphalan, increasingly, India, Inspected, inspection, intangible, inventory, invited, Jiangsu, Jianguo, Jintou, joint, KPMG, Larry, Lastly, lawfully, leave, lie, LLP, massive, maximize, mechanism, Memorandum, message, minimally, missing, mix, municipal, narcotic, narrow, Navigating, NDRL, NHSA, NMPA, nonclinical, Nonemployee, NRDL, ofIbritumomab, ofMelphalan, orMelphalan, ourMelphalan, output, palliative, physician, pilot, policing, population, potent, proliferation, Province, provincial, psychotropic, publish, pure, purporting, Quarantine, RDL, readily, recoverability, recoverable, refocused, regularly, reject, rejection, reorganization, repeat, Republic, reshuffle, resubmit, retail, Road, robust, routine, SAC, SAIC, SAMR, Science, screen, sequential, shortage, social, society, speak, statistical, subgroup, substantive, succeed, sweeping, switch, symbol, TDF, tender, tenofovir, thatMelphalan, theWuxi, threshold, Tower, trend, Trump, unadjusted, understated, undertaken, undesirable, undiscounted, unfamiliar, uniform, unqualified, UntilMelphalan, USD, venture, volume, Wei, whenMelphalan, win, won, Wuxi, Zhang, Zone, Zonein

Removed: aperformance, assured, awarded, begun, biomarker, Bioventure, borrowing, buyer, calling, cancelled, Careful, Celgene, CFDA, clearance, collectibility, competitor, copy, core, Corporation, corroborated, culture, Diligent, Dr, earned, eligible, eliminate, EMA, employ, encourage, entrepreneurialism, environment, European, eventual, exchanged, extend, federally, fewer, fixed, fluid, forfeited, forfeiture, Gate, HCC, hepatocellular, history, incremental, ineffective, infrequently, innovation, intensely, issuable, kft, lending, Likewise, maturity, mission, molecule, myeloid, nationally, nonqualified, notice, obligated, observable, orphan, outcome, outlined, ovarian, partially, periodically, persuasive, posted, preclude, priced, prudent, receivable, Red, regionally, Remeasurement, reportable, resource, restructured, retention, reversal, Room, setback, skilled, spending, Street, suffered, supplemental, suspended, thalidomide, thatperformance, toxic, tubulin, turnover, uneconomical, unsettled, vested, Vice, Web, withperformance, yielded, ZEVALIN®therapeutic

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

CASI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION BY CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of CASI Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ken K. Ren, as Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company

This certificate is being made for the exclusive purpose of compliance by the Chief Executive Officer of the Company with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002, and may not be used by any person or for any reason other than as specifically required by law.

		/s/ Ken K. Ren
March 29, 2019		Ken K. Ren Chief Executive Officer